Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ospemifene for Vulvovaginal Atrophy and Dyspareunia
NCT02784613Phase 4Completed
- Start
- Jul 2015
- Primary completion
- Feb 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of ospemifene in Vulvovaginal atrophy (VVA) and dyspareunia. Primary endpoint: Visible Changes to the Vulva, Vestibule and Vaginal Region on Photography at 20 weeks. Started Jul 2015; status: completed.
02
Drugs
ospemifene
03
Conditions
Vulvovaginal atrophy (VVA)dyspareunia
Beyond the preview
Go deeper on NCT02784613.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02784613.